We believe we are on journey toward making a significant contribution with an oral anti-TNF drug. |
We believe we have orders for a further Sfr200m to Sfr250m in the fourth quarter. |
We expect the decision to come in the next few days. |
We have both decided the second time around is much better, |
We have not identified anyone who could significantly speed up the agreed delivery timelines for the first half of 2006, but we have been able to identify partners to insure against breakdowns in supply and partners to broaden geographic coverage. |
We have taken this unique step, which is unlike any initiative undertaken by Roche, to help ensure that the right medicines in the right formulation are available locally. We want to use the knowledge we have developed to help strengthen local manufacturing capability and hope to help as many manufacturers as possible in these hardest hit countries by sharing our knowledge, so that they can learn and benefit from our technology. |
We stand by the guidance of February when we forecast 1.1 to 1.2 billion Swiss francs for pandemic use. That is the best estimate we can give on the government orders we have. |